Methods of treating inflammatory and autoimmune diseases with natalizumab
AssigneeBiogen MA Inc.
InventorIvan Lieberburg
Life of this patent
Estimating the term…
Abstract
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Claims76
A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
- (a) administering a pharmaceutically effective amount of natalizumab;
- (b) monitoring the patient for indicators of progressive multifocal leukoencephalopathy;
- and
- (c) discontinuing the administration of natalizumab in the presence of indicators of progressive multifocal leukoencephalopathy;
- wherein the monitoring improves the safety of the treatment.
A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
- (a) removing a sample of blood from the patient;
- (b) testing the serum or plasma of the sample for the presence of IgG antibodies to JCV;
- (c) initiating treatment of the patient with natalizumab in the event the sample is negative for IgG antibodies to JCV;
- (d) monitoring the patient for indicators of progressive multifocal leukoencephalopathy;
- and
- (e) discontinuing the administration of natalizumab in the presence of indicators of progressive multifocal leukoencephalopathy;
- wherein the testing and monitoring improve the safety of the treatment.
A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
- (a) removing a sample of blood from the patient;
- (b) testing the serum or plasma of the sample for the presence of IgG antibodies to JCV;
- (c) initiating treatment of the patient with natalizumab in the event the sample is positive for IgG antibodies to JCV;
- (d) monitoring the patient for indicators of progressive multifocal leukoencephalopathy;
- and
- (e) discontinuing the administration of natalizumab in the presence of indicators of progressive multifocal leukoencephalopathy;
- wherein the testing and monitoring improves the safety of the treatment.
A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
- (a) removing a sample of blood from the patient;
- (b) testing the sample for the presence of IgG antibodies to JCV;
- (c) initiating treatment of the patient with natalizumab;
- (d) informing the prescribing physician about the mental and physical symptoms of progressive multifocal leukoencephalopathy;
- (e) informing the patient about the mental and physical symptoms of progressive multifocal leukoencephalopathy and instructing the patient to report to the physician in the presence of at least one symptom;
- (f) monitoring the patient for indicators of progressive multifocal leukoencephalopathy;
- and
- (g) discontinuing the administration of natalizumab in the presence of indicators of progressive multifocal leukoencephalopathy;
- wherein the testing, information, and monitoring improve the safety of the treatment.
Dependencies are inferred from the claim text.